1. Home
  2. ARCC vs ILMN Comparison

ARCC vs ILMN Comparison

Compare ARCC & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARCC
  • ILMN
  • Stock Information
  • Founded
  • ARCC 2004
  • ILMN 1998
  • Country
  • ARCC United States
  • ILMN United States
  • Employees
  • ARCC N/A
  • ILMN N/A
  • Industry
  • ARCC Finance/Investors Services
  • ILMN Medical Specialities
  • Sector
  • ARCC Finance
  • ILMN Health Care
  • Exchange
  • ARCC Nasdaq
  • ILMN Nasdaq
  • Market Cap
  • ARCC 15.8B
  • ILMN 16.0B
  • IPO Year
  • ARCC 2004
  • ILMN 2000
  • Fundamental
  • Price
  • ARCC $22.43
  • ILMN $98.18
  • Analyst Decision
  • ARCC Buy
  • ILMN Buy
  • Analyst Count
  • ARCC 9
  • ILMN 15
  • Target Price
  • ARCC $23.00
  • ILMN $123.67
  • AVG Volume (30 Days)
  • ARCC 3.1M
  • ILMN 1.3M
  • Earning Date
  • ARCC 10-29-2025
  • ILMN 11-03-2025
  • Dividend Yield
  • ARCC 8.54%
  • ILMN N/A
  • EPS Growth
  • ARCC N/A
  • ILMN N/A
  • EPS
  • ARCC 2.03
  • ILMN 7.91
  • Revenue
  • ARCC $3,011,000,000.00
  • ILMN $4,284,000,000.00
  • Revenue This Year
  • ARCC $3.21
  • ILMN N/A
  • Revenue Next Year
  • ARCC $5.09
  • ILMN $2.76
  • P/E Ratio
  • ARCC $11.06
  • ILMN $12.41
  • Revenue Growth
  • ARCC 6.85
  • ILMN N/A
  • 52 Week Low
  • ARCC $18.26
  • ILMN $68.70
  • 52 Week High
  • ARCC $23.84
  • ILMN $156.66
  • Technical
  • Relative Strength Index (RSI)
  • ARCC 51.10
  • ILMN 48.37
  • Support Level
  • ARCC $22.15
  • ILMN $93.94
  • Resistance Level
  • ARCC $22.42
  • ILMN $100.82
  • Average True Range (ATR)
  • ARCC 0.21
  • ILMN 2.61
  • MACD
  • ARCC 0.02
  • ILMN -0.27
  • Stochastic Oscillator
  • ARCC 67.43
  • ILMN 43.67

About ARCC Ares Capital Corporation

Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: